Abstract
PURPOSE: MN-221 is a novel, highly selective β2 agonist in development for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). MN-221 has a greater selectivity for the human β2 receptors than commonly used β2 agonists (i.e., albuterol, levalbuterol, terbutaline). MN-221 has been studied in both stable asthmatics and in acute exacerbations of asthma with results indicating increased effects on FEV1 and minimal effects of heart rate and blood pressure. A 1-hour infusion has produced a markedly greater improvement in FEV1 than the 2-hour regimen ion stable asthmatics.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
